about
Cerebral MR spectroscopy in neurologically asymptomatic HIV-infected patients.Present and future possibilities for early diagnosis of hepatocellular carcinomaPlasma interleukin-18 reflects severity of ulcerative colitis.Epidemiological characteristics of inflammatory bowel disease in North-Eastern Poland.Plasma matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 as biomarkers of ulcerative colitis activity.Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe.Pigment epithelium-derived factor and matrix metalloproteinase-9 in liver cirrhosisEfficacy and safety of danoprevir-ritonavir plus peginterferon alfa-2a-ribavirin in hepatitis C virus genotype 1 prior null responders.Symptomatic co-infection with Babesia microti and Borrelia burgdorferi in patient after international exposure; a challenging case in Poland.Real-world effectiveness and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C: AMBER study.The effects of CD4 nadirs on vessel stiffness in HIV patients undergoing antiretroviral therapy.Evaluation of endothelial function and arterial stiffness in HIV-infected patients: a pilot study.Rapid decline of viral RNA in chronic hepatitis C patients treated once daily with IDX320: a novel macrocyclic HCV protease inhibitor.Concentrations of soluble Fas and soluble Fas ligand as indicators of programmed cell death among patients coinfected with Human Immunodeficiency Virus and Hepatitis C Virus.The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus.High prevalence of genotype 4 among hepatitis C virus-infected intravenous drug users in north-eastern Poland.Transforming growth factor beta1 and prostaglandin E2 concentrations are associated with bone formation markers in ulcerative colitis patients.Pigment epithelium-derived factor in ulcerative colitis: possible relationship with disease activity.Evolving patterns of HIV-1 transmitted drug resistance in Poland in the years 2000-2008.Increased plasma transforming growth factor-beta1 is associated with disease progression in HIV-1-infected patients.HCV coinfection possibly promotes left ventricular dysfunction development: analysis of brain natriuretic peptide serum levels in HCV/HIV-coinfected and HIV-monoinfected patients.Comparative analysis of the new chronic kidney disease epidemiology collaboration and the modification of diet in renal disease equations for estimation of glomerular filtration rate in HIV type 1-infected subjects.Opportunistic infections and other AIDS-defining illnesses in Poland in 2000-2002.Serum ADAMTS-13 Levels as an Indicator of Portal Vein Thrombosis.Significance of Heparin-Binding Protein and D-dimers in the Early Diagnosis of Spontaneous Bacterial PeritonitisEffects of ulcerative colitis activity on plasma and mucosal prostaglandin E2 concentrationEffect of ulcerative colitis activity on plasma concentration of transforming growth factor beta1The possible association between serum cholesterol concentration and decreased bone mineral density as well as intravertebral marrow fat in HIV-1 infected patientsIntestinal fatty acid binding protein (I-FABP) as a possible biomarker of ileitis in patients with ulcerative colitisPlasma interleukin-18 is associated with viral load and disease progression in HIV-1-infected patientsIs there any influence of immune deficit on procalcitonin results?
P50
Q33186698-73DC97D0-CCD3-4FD6-9A01-73B498F21FEDQ33612167-C2ACC706-D3C3-4F49-AD4C-740721DCB4C3Q34605860-D8252600-F2EA-4CA2-99FD-3C44C76DB44BQ35010645-2A4E5257-3881-44DC-9FF2-79C07C8D486AQ36180595-10D06294-04F1-4D73-A5BD-8372273D78D0Q36543845-DCD5EE81-8957-452A-BB90-05110300D17DQ37311888-6CAF1A00-6E11-4982-BF6E-0B013F4FFF39Q37544611-6C00AB96-9D89-44D4-BF66-B7533D9A57EBQ39097670-528A44CF-F426-4C02-BAB9-67825FDDF4C7Q39406860-72FCB971-0A5C-4A8E-8A12-9502E6C0C954Q40182082-58B994A3-D43C-4FD3-B715-A96262FFD2D7Q41646346-56B82245-6F9D-4650-8311-0CC1EB60E70FQ42978475-D1B01202-9BEE-436F-AC0F-AD2EC8A6CFEEQ43031484-2B99EF83-42E0-4E8B-82C6-E1CD7ABA9588Q43046668-D70FC631-C543-45FF-B6D6-57C817F25FB6Q43046733-73C8134B-6CCD-497C-9B4A-BA08BFEEC296Q43550065-14B3E4DC-34D8-4DAA-8419-C3E8C7F1FC2AQ43985033-ED5435C4-CA35-46B2-AC62-74A4B0692CFBQ46532056-90B92609-33B6-4DBD-9956-B8EF494020C3Q47958615-958F6D4B-A4D9-4553-B2A3-6F024DD59829Q48430763-1063C859-FCE3-45AF-8453-B97AE0685283Q51607580-F20496CD-C22E-449E-927A-06C8B01B4B4AQ53768335-6C3E7E10-66B7-4F97-A682-3E5FC80578F1Q55193928-467826E8-22A1-48BD-BBF3-5FF64C2A9E34Q58604321-265F983B-E0A1-4617-AD9F-222F5F037759Q73179620-EB296B3F-BE70-4F0E-B266-8608240499DAQ74344176-49DF3EBA-A65E-4ECB-A0BB-6B44D8CDC875Q79767624-D43AA6EA-ABC4-471F-A7EB-2589D85A8B4FQ80507477-D1B32878-90C3-479F-BEF5-29F1DDB9BF9AQ81037618-060291BD-BE70-4EAD-B04F-39B2AEFFD30EQ84957084-3C315C24-480A-4844-9D3C-385CE65F4C34
P50
description
Polish researcher
@en
polski naukowiec
@pl
taighdeoir Polannach
@ga
wetenschapper
@nl
name
Alicja Wiercińska-Drapało
@ast
Alicja Wiercińska-Drapało
@ca
Alicja Wiercińska-Drapało
@de
Alicja Wiercińska-Drapało
@en
Alicja Wiercińska-Drapało
@es
Alicja Wiercińska-Drapało
@fr
Alicja Wiercińska-Drapało
@ga
Alicja Wiercińska-Drapało
@gl
Alicja Wiercińska-Drapało
@it
Alicja Wiercińska-Drapało
@nl
type
label
Alicja Wiercińska-Drapało
@ast
Alicja Wiercińska-Drapało
@ca
Alicja Wiercińska-Drapało
@de
Alicja Wiercińska-Drapało
@en
Alicja Wiercińska-Drapało
@es
Alicja Wiercińska-Drapało
@fr
Alicja Wiercińska-Drapało
@ga
Alicja Wiercińska-Drapało
@gl
Alicja Wiercińska-Drapało
@it
Alicja Wiercińska-Drapało
@nl
altLabel
Alicja Wiercinska-Drapalo
@en
prefLabel
Alicja Wiercińska-Drapało
@ast
Alicja Wiercińska-Drapało
@ca
Alicja Wiercińska-Drapało
@de
Alicja Wiercińska-Drapało
@en
Alicja Wiercińska-Drapało
@es
Alicja Wiercińska-Drapało
@fr
Alicja Wiercińska-Drapało
@ga
Alicja Wiercińska-Drapało
@gl
Alicja Wiercińska-Drapało
@it
Alicja Wiercińska-Drapało
@nl
P214
P1153
55400429100
P1412
P1559
Alicja Wiercińska-Drapało
@pl
P21
P214
P27
P31
P3124
P496
0000-0001-5921-1409
P735
P7859
viaf-305223732